199 related articles for article (PubMed ID: 16609824)
1. Persistence with weekly alendronate therapy among postmenopausal women.
Lo JC; Pressman AR; Omar MA; Ettinger B
Osteoporos Int; 2006; 17(6):922-8. PubMed ID: 16609824
[TBL] [Abstract][Full Text] [Related]
2. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
4. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
5. Differences in persistence among different weekly oral bisphosphonate medications.
Sheehy O; Kindundu CM; Barbeau M; LeLorier J
Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
[TBL] [Abstract][Full Text] [Related]
6. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
7. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
[TBL] [Abstract][Full Text] [Related]
8. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
Rabenda V; Mertens R; Fabri V; Vanoverloop J; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
[TBL] [Abstract][Full Text] [Related]
9. Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System.
Hui RL; Adams AL; Niu F; Ettinger B; Yi DK; Chandra M; Lo JC
J Manag Care Spec Pharm; 2017 Apr; 23(4):503-512. PubMed ID: 28345435
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
11. Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study.
Carbonell-Abella C; Pages-Castella A; Javaid MK; Nogues X; Farmer AJ; Cooper C; Diez-Perez A; Prieto-Alhambra D
Calcif Tissue Int; 2015 Dec; 97(6):535-41. PubMed ID: 26202819
[TBL] [Abstract][Full Text] [Related]
12. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Brookhart MA; Avorn J; Katz JN; Finkelstein JS; Arnold M; Polinski JM; Patrick AR; Mogun H; Solmon DH
Am J Med; 2007 Mar; 120(3):251-6. PubMed ID: 17349448
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
14. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
[TBL] [Abstract][Full Text] [Related]
15. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
Turbí C; Herrero-Beaumont G; Acebes JC; Torrijos A; Graña J; Miguélez R; Sacristán J; Marín F
Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
[TBL] [Abstract][Full Text] [Related]
16. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
18. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Lai PS; Chua SS; Chew YY; Chan SP
J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
20. Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.
Adami G; Jaleel A; Curtis JR; Delzell E; Chen R; Yun H; Daigle S; Arora T; Danila MI; Wright NC; Cadarette SM; Mudano A; Foster J; Saag KG
J Bone Miner Res; 2020 Mar; 35(3):478-487. PubMed ID: 31714637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
